Uncategorized - malecare.org

Xtandi Shows Activity in Men with Prostate Cancer Resistant to Chemotherapy and Zytiga

Since its FDA approval in 2011 FDA abiraterone (Zytiga) has supplanted docetaxel (chemotherapy), other than perhaps Provenge, as preferred first-line treatment for metastatic castrate-resistant prostate cancer. August 2012 saw the FDA approval of enzalutamide (Xtandi) for the treatment of castrate-resistant prostate cancer after chemotherapy. Researchers performed a retrospective chart review at a large medical oncology [...]

By Malecare|2017-10-19T10:48:35-04:00February 13th, 2014|abiraterone acetate, Advanced Prostate Cancer, Chemo Therapy, Chemo Therapy Failure, Drugs & Treatments, enzalutamide, Provenge, Uncategorized, Xtandi, Zytiga|0 Comments

Circulating Tumor Cell Enumeration in Metastatic Neuroendocrine Prostate Cancer and Castration-Resistant Prostate Cancer

An uncommon, but very aggressive form of prostate cancer is known as Neuroendocrine prostate cancer (NEPC). It is generally accepted that Circulating Tumor Cell (CTC) counts as measured by CellSearch (a method to catch and count these cells in the blood) are prognostic for most men with metastatic prostate cancer (mPC), but are not well [...]

By Malecare|2017-10-19T10:48:35-04:00February 12th, 2014|Advanced Prostate Cancer, CTCs, General Information, neuroendocrine prostate cancer, Research, Uncategorized, Understanding APC|0 Comments

Denosumab for the Prevention of Skeletal Events in Men with Castration-Resistant Advanced Prostate Cancer

From: the 2014 ASCO GU Meeting Abstract No: 35 Researchers have found in a randomized controlled trial of men with metastatic castration-resistant prostate cancer (mCRPC) the use of the treatment denosumab was superior to the more commonly used zoledronic acid (ZA) for reducing skeletal-related events (SRE). SREs are defined as a pathological fracture, surgery or [...]

By Malecare|2014-02-11T15:14:16-05:00February 11th, 2014|Advanced Prostate Cancer, bisphosphonates, Bone Metastases, Clinical Trials, Clinical Trials, denosumab - Xgeva, Drugs & Treatments, Uncategorized, Understanding APC, Xgeva, Zometa|1 Comment

From ASCO GU – Long Term Data Show Ra-223 Safe in Advanced Prostate Cancer

The novel radiopharmaceutical radium-223 (Xofigo) appears to have long term safety with minimal adverse events. In an updated report, given at ASCO GU, on the ALSYMPCA trial of radium-233 (Xofigo), the researchers have found that there is no major safety issues identified within ~1.5 years after the completion of treatment in a population of men [...]

By Malecare|2017-10-19T10:48:37-04:00February 7th, 2014|Advanced Prostate Cancer, Bone Metastases, Drugs & Treatments, radiopharmaceuticals, Uncategorized, Xofigo|1 Comment

Zytiga in Québec, Radium-223 in England & Lets Change Our Antiquated Approval Nonsense

Men with metastatic castration-resistant prostate cancer (mCRPC) in Québec, Canada now have access to Zytiga (abiraterone acetate) prior to having chemotherapy. Effective February 3, 2014, the province has added ZYTIGA to the public drug formulary for the treatment of mCRPC in men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy (ADT). [...]

By Malecare|2014-02-06T22:31:17-05:00February 6th, 2014|abiraterone acetate, Advanced Prostate Cancer, Advocacy, Alpharadin (radium-223), Drugs & Treatments, Early/Expanded Access Programs, General Information, radiopharmaceuticals, Uncategorized, United Kingdom - England, Northern Ireland, Scotland & Wales, Xgeva, Xofigo, Zytiga|2 Comments